The U.S. Food and Drug Administration has warned that the antiobesity drug Belviq (Ingredient: lorcaserin) could increase the risk of cancer.
“The FDA is alerting the public that results from a clinical trial assessing safety show a possible increased risk of cancer with the weight management medicine Belviq and Belviq XR,” the agency said in a news release. “At this time, the cause of the cancer is uncertain, and we cannot conclude that lorcaserin contributes to the cancer risk.”
However, the agency wanted to make the public aware of this potential risk, the FDA added. The regulator then stressed that it is continuing to evaluate the clinical trial results and will communicate its conclusions and recommendations when it has completed its review.
Following the announcement, the Korean regulator said that it had confirmed the FDA’s statement regarding Belviq.
“Following the announcement of the U.S. FDA, we will distribute a safety letter in Korea to inform experts and patients of this information and asked for their caution in taking the drug,” the Ministry of Food and Drug Safety said.
Belviq is an appetite suppressant that acts on the central nervous system, which nabbed the FDA nod in 2012. In Korea, Ildong Pharmaceutical has been marketing the drug since February 2015.
<© Korea Biomedical Review, All rights reserved.>